4-Thiazolidinone derivative Les-3833 effectively inhibits viability of human melanoma cells through activating apoptotic mechanisms by Nataliya Finiuk et al.
129
www.cmj.hr
Aim To evaluate cytotoxic action of 4-thiazolidinone deriv-
ative Les-3833 and study the mechanisms of its pro-apop-
totic action toward human melanoma cells and human tu-
mor cell lines of other tissue origin.
Methods The effect of Les-3833 or doxorubicin on the vi-
ability of 9 cell lines was studied using MTT assay, while 
human melanoma cells of WM793 line were additionally 
examined using light and fluorescent microscopies for 
evaluating cytomorphological changes. The Western-blot 
and flow cytometric analyses were carried out to study sig-
naling pathways of melanoma cell cycling and death.
Results Les-3833 was the most efficient against melano-
ma cells. Its half maximal inhibitory concentration (IC50) 
was 0.22 μg/mL for WM793 cells and 0.3 μg/mL for SK-Mel-
28 melanoma cells. For human lung A549, breast MCF-7, 
colon HCT116, and ovarian SKOV3 carcinoma cell lines IC50 
was in between 2.5 to >5.0 μg/mL. Les-3833 was relative-
ly not toxic (IC50 > 5 μg/mL) for human embryonic kidney 
HEK293 cells. Results of Annexin V/PI staining of melanoma 
cells and activation of caspase 3, PARP, MAPK, and EndoG 
protein suggest apoptosis in Les-3833-treated cells. Les-
3833 also induced ROS production in melanoma cells and 
their arrest in G0/G1 phase of cell cycle.
Conclusion Novel 4-thiazolidinone derivative Les-3833 is 
effective against human melanoma cells in vitro, and such 
effect is tumor specific since it is much less pronounced in 
human carcinoma and leukemia cells. In melanoma cells 
Les-3833 induces apoptosis (morphological changes and 
increased pro-apoptotic proteins), ROS production, and ar-
rest in G0/G1 phase of cell cycle.
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Melanoma arises from the melanin-producing skin cells 
- melanocytes. It exhibits high metastasis potential and 
poor prognosis in treated patients with a survival rate of 
16.1% (1).
Since there is no effective anti-melanoma drugs available 
in clinics, melanoma remains as one of the most difficult 
for chemotherapeutic treatment (2). That is why, the im-
munomodulating approaches were applied. They include 
the application of cytokines (high-dose of interferon al-
fa-2b (Intron A) and interleukin-2), and of the antibodies 
(ipilimumab, anti-CTLA4 and anti-PD-1 antibodies). Other 
new strategies for melanoma treatment are based on us-
ing immune modulators, BRAF inhibitors (Vemurafenib) 
and MEK (mitogen-activated protein kinase) inhibitors. All 
these drugs are very costly, and some of them can be high-
ly toxic and not effective (3,4). Subsequently, any success 
in creating novel anti-melanoma drug is a big challenge 
in development of effective chemotherapy for this highly 
malignant tumor.
Usually, the chemotherapeutic compounds impair not 
only tumor cells but also exhibit significant negative side 
effects toward non-tumor cells. In addition, drug resistance 
of the melanoma cells develops with high rate. Targeting 
cell proliferation and apoptotic pathways are principal ap-
proaches for understanding pathogenesis of most diseas-
es including cancer. Thus, the agents capable of blocking 
cell cycle and inducing apoptosis of tumor cells are attrac-
tive as novel anticancer medicines (5).
4-Thiazolidinones derivatives have been used for the de-
sign of novel drugs (6,7). These substances demonstrate 
wide spectrum of biological effects, including antibacterial, 
anti-mycotic, hypoglycemic, antineoplastic, immunomod-
ulating, and antidiabetic (8-12). Moreover, 4-thiazolidino-
ne core possesses high capacity for chemical modifica-
tions that opens great possibilities in the development of 
novel derivatives. Principal approaches in modification of 
4-thiazolidinone-bearing compounds are focused on the 
creation of new antibacterial, antiviral, anti-inflammatory, 
antidiabetic, and anticancer agents (12). 4-Thiazolidinones 
were also used for treatment of neuropathy and nephrop-
athy (8). Such compounds induced changes in Ca2+ level, 
the mitogen-activated protein kinases (MAPK) activation, 
reactive oxygen species (ROS) production and endoplas-
mic reticulum stress (5,13).
Recent achievements in the medicinal chemistry of 
4-thiazolidinones have significantly stimulated the 
development of studies addressed on a design of new an-
ticancer agents (5). It was reported that products of the 
hybridization of thiazolidine-2,4-diones scaffolds with dif-
ferent bioactive molecules possessed anticancer activity 
(5). It was shown that novel 5-ene-4-thiazolidinones pos-
sessed a selective anti-leukemic action (14). A search for 
novel potent antitumor pharmaceuticals demonstrating 
high selectivity and low toxicity to normal cells is currently 
strongly prioritized (5,8,12-14).
In the present work, we evaluated novel synthetic 4-thiaz-
olodinone derivative, the Les-3833, as a potent anti-mela-
noma agent, and compared its toxic action toward tumor 
cells of other tissue origin, as well as studied the molecu-




The heterocyclic 4-thiazolidinone derivative Les-3833 (Fig-
ure 1) belongs to the pyrazoline-thiazolidinone-isatins 
conjugates and was synthesized as described previously 
(15). Stock solution of Les-3833 (10 mM) was prepared in 
the dimethyl sulfoxide (DMSO, REALAB, Kyiv, Ukraine), and 
dissolved in cell culture medium before addition to the cell 
culture medium. Doxorubicin (Dox, TEVA Pharmachemie 
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B.V., Haarlem, the Netherlands) was used, as a reference an-
ticancer drug.
Cell culture
Human ovarian carcinoma SKOV3 cells and human mela-
noma WM793 cells were received from the American type 
culture collection (ATCC, Minnesota, USA) and were pro-
vided by Dr O. Stasyk (Institute of Cell Biology, National 
Academy of Sciences of Ukraine, Lviv, Ukraine). Human 
melanoma SK-MEL-28 cells, human lung carcinoma A549 
cells, human breast adenocarcinoma MCF-7 cells, human 
embryonic kidney HEK293 cells were obtained from the 
collection at R.E. Kavetsky Institute of Experimental Pathol-
ogy, Oncology and Radiobiology (Kyiv, Ukraine). Human 
colon carcinoma HCT116 cells, human keratinocytes of 
HaCat line and human leukemia K562 cells were donat-
ed from a collection of the Institute of Cancer Research 
at Vienna Medical University (Vienna, Austria). Cells were 
grown in the RPMI-1640 or DMEM (Sigma-Aldrich, St. Lou-
is, USA) culture media supplemented with 10% fetal bo-
vine serum (Sigma-Aldrich, St. Louis, USA). Cells were incu-
bated in the CO2-thermostate at 37°C in the atmosphere 
containing 5% CO2.
Anti-proliferative assay
In vitro screening of the anticancer action of the synth-
sized compound Les-3833 and doxorubicin towards tu-
mor cell lines was measured using the 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyl-tetrazolium bromide (MTT) 
test (Sigma-Aldrich, St. Louis, USA). Cells were seeded for 
the night in 100 μL in the 96-well plates: substrate-de-
pendent cells were seeded at the concentration of 2000 
cells/well and suspension cells - at 5000 cells/well. Then, 
the cells were treated with the Les-3833 and doxorubicin 
(none; 0.1; 0.25; 0.5; 1.0; 5.0; 10.0 μg/mL) and incubated 
for next 72 h. The mitochondrial dehydrogenases con-
verted the MTT to its colored product and water insol-
uble MTT formazan (additionally dissolved in the DMSO) 
was used to determine the viable cells. Product of the re-
action was determined by an Absorbance Reader BioTek 
ELx800 (BioTek Instruments, Inc., Winooski, VT, USA) at 620 
nm wavelength.
In order to study time-dependent cytotoxicity of Les-3833 
and Dox, cells of WM793 line were treated with these com-
pounds (none; 0.1; 0.25; 0.5; 1.0; 5.0; 10.0 μg/mL) and incu-
bated for the subsequent 6, 24, 48 and 72 h. After that, MTT 
assay was used to determine the viable cells.
For estimating the impact of ROS’s scavengers (N-acetyl-
cysteine (NAC) and ascorbic acid (AA) (Sigma-Aldrich, St. 
Louis, USA)) on the cytotoxicity of Les-3833 and Dox on 
WM793 cells were used in a combination with cell pre-
treatment for 30 min with the non-toxic concentrations of 
ROS scavengers (NAC was used in 1.0; 2.0 mM: AA - at 25.0; 
100.0 μM) (14).
Fluorescent microscopy
The cells of WM793 line were seeded on the glass micro-
scopic slides in the 12-well plates. Double staining of cells 
with FITC-conjugated Annexin V and Propidium iodide (PI) 
(both from Sigma-Aldrich, St. Louis, USA) was used to iden-
tify early apoptotic events in human melanoma WM793 
cells treated with Les-3833 and Dox (both used at 0.25 µg/
mL concentration) for 72 h. After that, cells were washed 
with 1 × phosphate buffered saline (PBS), and incubated 
for 15 min with the Annexin V binding buffer containing 
1/20 volume of FITC-conjugated Annexin V solution and 
PI (20.0 μg/mL) (14). The cells were analyzed under Zeiss 
fluorescent microscope (Carl Zeiss, Jena, Germany) using 
AxioImager A1 camera.
In 72 h after the addition of the tested compounds at 1 µg/
mL concentration, the cells were stained with 0.2-0.5 µg/mL 
of the DNA-specific fluorescent dye Hoechst 33342 (Sigma-
Aldrich, St. Louis, USA). The cells were also stained by the 
poly-specific dye Acridine orange (AO, 0.3-1.0 µg/mL, Sigma-
Aldrich, St. Louis, USA). The cells were incubated for next 20-
30 min and examined using a Zeiss fluorescent microscope 
(Carl Zeiss, Jena, Germany) using AxioImager A1 camera.
Western-blot analysis
Proteins of cells treated with the tested compound (Dox 
was used in 0.25 µg/mL concentration, Les-3833 - in 0.25 
and 0.5 µg/mL) were separated by the SDS/PAGE gel-elec-
trophoresis and transferred onto a polyvinylidene difluo-
ride (PVDF) membrane, as described (13). The antibodies 
for Cleaved Caspase 3 (Asp175), Cleaved PARP (Asp214), 
anti-phospho-ERK1/2 (phospho-p44/42, Thr 202/Tyr 204), 
anti-EndoG, anti-STAT3, anti-phospho-Rb (Ser 807/811), 
(Cell Signaling Technology, New England Biolabs GmbH, 
Austria), anti-Cdk2 (SantaCruzBiotechnology, Inc., Dallas, 
Texas, USA), anti-beta-actin monoclonal mouse AC-15 
(Sigma-Aldrich, St. Louis, USA) were used. Secondary rab-
bit and mouse peroxidase-labeled antibodies (CellSig-
naling Technology, New England Biolabs GmbH, Aus-
tria) were used at working dilution of 1:5000.
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Cell cycle analysis
To analyze cell cycle distribution, WM793 cells were seeded 
into 6-well plates and then treated with the Les-3833 or 
doxorubicin at 0.25 µg/mL for 72 h. Cells were prepared as 
described (14), stained with PI (5 μg/mL) and analyzed by 
flow cytometry (Becton Dickinson, PaloAlto, CA, USA).
Statistical analysis
Results were presented as the mean ± standard deviation 
(SD). GraphPad Prism 6 was used for results analysis, chart-
ing, t test or two-way ANOVA test. P < 0.05 was set as the 
level of statistical significance.
ReSuLtS
Anticancer activity in vitro of 4-thiazolidinone derivative 
Les-3833
In vitro screening of the cytotoxic action of Les-3833 and 
doxorubicin against different tumor cell lines was per-
formed by MTT assay. The results of such testing of human 
breast adenocarcinoma MCF-7 cells, human colon carci-
noma HCT116 cells, human ovarian carcinoma SKOV3 cells 
are presented in Figure 2 and summarized in Table 1. The 
Les-3833 demonstrated very low activity against the ovar-
ian carcinoma SKOV3 cells (half maximal inhibitory con-
centration (IC50) > 5 μg/mL), and low activity against other 
human carcinoma cells of A549, HCT116, and MCF-7 lines 
(IC50 was 2.5 ± 0.19 μg/mL (A549 cells), 3.4 ± 0.32 μg/mL 
(HCT116 cells), and 4.5 ± 0.36μg/mL (MCF-7 cells)). The cy-
totoxicity index (ie, IC50) of doxorubicin in all above noted 
cell lines was notably higher than of the Les-3833 (Figure 2, 
Table 2). An increase of the panel of tumor cells treated with 
the Les-3833 and doxorubicin by human myeloid leukemia 
K562 cells growing in suspension culture did not reveal a 
significant cytotoxic activity of either Les-3833 or doxoru-
bicin (IC50 > 5 μg/mL for both). The Les-3833 was less toxic 
(IC50 > 5μg/mL) than the doxorubicin (IC50 = 3.2 ± 0.42 μg/
mL) toward human embryonic kidney cells of HEK293 line 
and toward human keratinocytes of HaCat line (IC50 for Les-
3833 was 3.16 ± 0.41 μg/mL and IC50 for doxorubicin was 
0.47 ± 0.07 μg/mL, Figure 2, Table 1).
FIguRe 2. growth inhibiting activity of Les-3833 and dox toward different human cell lines. Cell vitality was estimated by the Mtt 
assay after 72 h of experiment. dox was used as a positive control.
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The anticancer effect in vitro of the Les-3833 changed 
drastically when human melanoma cells were treated. 
It was found (Figure 2, Table 2) that the IC50 value equals 
0.22 ± 0.03 μg/mL (WM793 cell line) and 0.3 ± 0.04 μg/mL 
(SK-Mel-28 cell line) which is more than 10 times lower 
than the IC50 noted above at the action of the Les-3833 to-
ward various human carcinoma cell lines. This allowed to 
suggest a higher specificity of the cytotoxic action of the 
Les-3833 toward melanoma cells, comparing with that in human carcinoma cells. Doxorubicin possessed similar to 
the Les-3833 cytotoxic effect toward human melanoma 
cells of WM793 cells (IC50 = 0.24 μg/mL) and SK-Mel-28cells 
(0.35 μg/mL) (Figure 2, Table 1). It should be noted that the 
cytotoxic effect of the Les-3833 toward human melanoma 
WM793 cells demonstrated both dose-dependence (Fig-
ure 2) and time-dependence (Table 2).
Cytotoxic action of Les-3833 toward human melanoma 
cells is accompanied by morphological changes in 
treated cells
Following the cytotoxic action of the Les-3833 in compari-
son with the doxorubicin (Figure 2, Table 1), it was reason-
able to estimate its cell damaging effect with the fluores-
cent microscopy. Treatment of human melanoma WM793 
cells with the Les-3833 or doxorubicin (both used at 1 µg/
mL) led to pro-apoptotic fragmentation of the nucleus, 
and chromatin condensation (Figure 1). Besides, most of 
the treated cells got a rounded shape. Red staining of cyto-
sol regions with Acridine orange suggested the activation 
of the lysosomes caused by the Les-3833 in the melanoma 
cells. It should be noted that doxorubicin induced less vis-
ible damages in these cells (Figure 3).
Les-3833 induces ROS production in human melanoma 
cells
It has been reported that several anticancer drugs in-
duced a production of ROS that could be partly 
tABLe 1. Cytotoxicity (IC50) of Les-3833 and dox toward different human cell lines (72 h, Mtt assay)
Cell line Les-3833 (ІС50±Sd, µg/mL) dox (ІС50±Sd, µg/mL)
Human melanoma WM793 cells 0.22 ± 0.03 0.24 ± 0.05
Human melanoma SK-MEL-28 cells 0.3 ± 0.04 0.35 ± 0.06
Human lung carcinoma A549 cells 2.5 ± 0.19 0.8 ± 0.05
Human colon carcinoma HCT116 cells 3.4 ± 0.32 0.44 ± 0.09
Human breast adenocarcinoma MCF-7 cells 4.5 ± 0.36 0.3 ± 0.04
Human ovarian carcinoma SKOV3 cells >5 2.0 ± 0.18
Human myeloid leukemia K562 cells >5 >5
Human embryonic kidney HEK293 cells >5 3.2 ± 0.42
Human keratinocytes HaCat cells 3.16 ± 0.41 0.47 ± 0.07
tABLe 2. exposure time-dependence of Les-3833 and dox 






 6 >5 3.90 ± 0.55
24 4.20 ± 0.40 2.50 ± 0.43
48 0.85 ± 0.11 2.00 ± 0.38
72 0.22 ± 0.03 0.24 ± 0.05
FIguRe 3. human melanoma cells WM793 after 72 h treatment 
with the studied compounds: (A), (B) – control; (C), (D) – doxo-
rubicin (positive control), (E), (F) – Les-3833, all used in 1 µg/
mL dose. Left – dIC image of treated cells stained with Acridine 
orange. Right – fluorescent image of treated cells (blue color – 
staining with fluorescent dNA-specific dye hoechst-33342, red 
and green color – staining with poly-specific fluorescent dye 
Acridine orange).
RECOOP for Common Mechanisms of Diseases 134 Croat Med J. 2017;58:129-39
www.cmj.hr
responsible for their cytotoxic action (17,18). In order to 
check whether the cytotoxicity of the Les-3833 relies on 
the intracellular ROS effects, we have used ROS scavengers 
such as NAC and AA. NAC is a precursor of glutathione and 
scavenger of H2O2 (14,18). The AA protects cells of the oxi-
dative stress and it is a scavenger of the hydroxyl radicals 
(14,19). Both NAC and AA distinctly inhibited the action of 
Les-3833 and enhanced a survival of human melanoma 
WM793 cells (Figure 4). Thus, ROS production induced by 
the Les-3833 in melanoma cells might be one of the mech-
anisms responsible for its antineoplastic activity.
Les-3833 induces an increase in ratio of Annexin 
V-positive melanoma cells
Human melanoma WM793 cells were stained after treat-
ment with FITC-conjugated Annexin V and PI, and then an-
alyzed by fluorescent microscopy. The amount of the An-
nexin V-positive (apoptotic) cells affected by the Les-3833 
(52.5%) was notable and higher than in control untreated 
cells (9.0%) (Figure 5). Under the action of the Les-3833, the 
amount of PI-positive (necrotic) cells increased (11.5%) in 
comparison to the control (2.5%), but much less than An-
nexin V-positive cells. These results suggest that the Les-
3833 caused melanoma cell death mainly via apoptosis 
mechanisms.
expression of apoptosis-related proteins in human 
melanoma cells treated with Les-3833
To verify that apoptosis is induced by a specific agent, one 
needs a confirmation of apoptosis expression by using 
at least three alternative approaches. Thus, we have con-
ducted the Western-blot analysis of the apoptosis-related 
proteins in the Les-3833-treated melanoma cells. The level 
of activated (cleaved) caspase 3 and inactivated (cleaved) 
poly-[ADP ribose]-polymerase-1 (PARP-1) was increased in 
melanoma cells treated for 72 h with the Les-3833 (Figure 
6). Besides, compound stimulated phosphorylation of the 
extracellular-regulated kinase 1/2 (ERK1/2) belonging to 
FIguRe 4. Protective effect of N-acetylcysteine (NAC) and ascorbic acid (AA) on the cytotoxic action of compound Les-3833 toward 
human melanoma WM793 cells. the Les-3833 was added to culture medium after 30 min pre-treatment of cells with NAC or AA. the 
viability of cells was determined by the Mtt assay after 72 h effect of the compound.
FIguRe 5. effect of the Les-3833 and doxorubicin on induction 
of apoptosis in human melanoma WM793 cells. Ratio of the 
Annexin V/FItC positive (AnV+) and Propidium iodide positive 
(PI+) cells was analyzed by the fluorescent microscopy study 
of the Annexin V/PI double staining of WM793 cells treated 
for 72 h with the Les-3833 or doxorubicin both used in 0.25 
µg/mL concentration. *P ≤ 0.05 (difference compared with the 
control).
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the MAPK family; induced the EndoG proteins; and dose-
dependently decreased the level of STAT3 (signal transduc-
er and activator of transcription 3) protein (Figure 6).
Changes in melanoma cell cycle pattern induced by 
Les-3833
A loss of cell cycle control can be the indicator of cell trans-
formation and carcinogenesis in the mammalians (20). 
We used the Western-blot analysis (Figure 7, A) and FACS 
analysis (Figure 7, B) in order to monitor changes in cell 
cycle-related proteins and changes in cell cycle pattern, 
correspondingly, under the action of the Les-3833 toward 
human melanoma WM793 cells. It was found that the treat-
ment of the melanoma cells with this compound caused a 
decrease of cyclin-dependent kinase 2 (Cdk2) as well as a 
decrease of the phosphorylated Rb (Retinoblastoma) pro-
tein (Figure 7, A). These regulators are responsible for the G1 
to S phase of cell cycle transition (14). The next step of our 
study was to use FACS analysis for monitoring the Les-3833
-induced changes in distribution of melanoma cell cycle 
phases. We have shown that the Les-3833 caused a 12.3% 
increase (comparing with the untreated cells) of cell num-
ber in the G0/G1 phase, while the doxorubicin significantly 
increased (42.5% more than in the control) a cell number in 
the G2/M phase (Figure 7, B). These data suggest a principle 
difference in the molecular mechanisms of action of the 
Les-3833 compared with that of the doxorubicin.
FIguRe 6. Pro-apoptotic proteins and transcription factor StAt3 
(Western-blot analysis) in human melanoma WM793 cells 
treated for 72 h with the Les-3833. C – control (untreated cells).
FIguRe 7. the results of measuring the effect of the Les-3833 (72 h treatment) on expression of cell cycle regulatory proteins and 
cell cycle distribution in human melanoma WM793 cells by using Western-blot analysis (A) or flow cytometry analysis (FACS) (B). C – 
control (untreated cells).
FIguRe 8. general scheme of signaling pathways induced by 
Les-3833 in melanoma cells.
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Summarizing, 4-thiazolidinone derivative Les-3833 pos-
sesses high cytotoxic action against human melanoma 
cells of two different lines (SK-Mel-28 and WM793). More-
over, it is much less effective in inhibiting the viability of 
human carcinoma cells of various lines, and it has a very 
low activity toward human leukemia K562 cells, human 
embryonic kidney HEK293 cells and human keratinocytes 
of HaCat line. The Les-3833 induced apoptosis in human 
melanoma cells with an activation of caspase 3 and influ-
enced the apoptosis-related proteins such as PARP, MAPKs, 
and Endo G. Probably, the Les-3833 affects the mitochon-
dria-mediated apoptotic pathway (Figure 8). It increased a 
number of the Annexin V-positive melanoma cells and a 
number of such cells in the G0/G1 phase of cell cycle. In 
addition, the Les-3833 action led to the intracellular accu-
mulation of ROS, since the cytotoxicity of this compound 
was inhibited by such ROS scavenges as N-acetylcysteine 
and ascorbic acid.
dISCuSSION
In our previous studies, cytotoxic action (MTT assay and 
Trypan blue exclusion test) of 3 structurally related 4-thiaz-
olidinones – compounds Les-3833, Les-3882 and Les-3288 
and Doxorubicin was compared for rat C6 glioma cells (21). 
It was revealed that melanoma cell lines were the most 
sensitive (IC50 in the MTT assay) to Les-3833, and that was 
the main reason for taking a decision to carry out more 
profound analysis of the molecular and cellular mecha-
nisms of the cytotoxic action of this agent.
This study confirmed using broad panel of human tumor 
cells that the Les-3833 possesses the highest cytotoxic ef-
fect toward melanoma cells of WM793 line and SK-Mel-28 
cell line. These effects were comparable with that of the 
doxorubicin. Thus, we have detected tumor tissue-specific 
toxic action of the Les-3833 for the melanoma cells, but 
not for other tumor cells of the epithelial origin. In case of 
mesenchyme-derived tumors Les-3833 had low activity 
against human myeloid leukemia K562 cells (IC50 > 5 µg/
mL), although in other studies a toxic action of this com-
pound was shown for murine leukemia L1210 cells (IC50 = 1 
µg/mL) (22).
Low cytotoxicity of the Les-3833 toward human embry-
onic kidney HEK293 cells and human keratinocytes HaCat 
cells should be stressed, since it is known that most an-
ticancer drugs act not only on well proliferating tumor 
cells but also exhibit negative side effects toward the 
non-tumor cells (6). As predicted, the doxorubicin 
was highly toxic for all types of human tumor cells under 
this study, as well for human embryonic kidney HEK293 
cells and human keratinocytes HaCat cells.
The revealed strong cytotoxic action of the Les-3833 to-
ward human melanoma cells was confirmed by its dam-
aging action on the morphology of these cells. It is known 
that specific pro-apoptotic changes in the morphology 
of the apoptotic cells can be observed in addition to bio-
chemical changes such as DNA damage, activation of cas-
pases, release of cytochrome C from mitochondria, or oth-
ers (23). During microscopic studies of Les-3833 action on 
human melanoma WM793 cells chromatin condensation 
typical for apoptosis was found. Strong activation of lyso-
somes (Acridine orange staining of cytosol regions in red 
color) under Les-3833 treatment should be noted, since it 
was even higher than such activation induced by the doxo-
rubicin. Acridine orange is a basic amino dye that possess-
es lysosomotropic action. After accumulation in lysosomes 
with acid pH, it demonstrates red fluorescence, while at 
neutral pH in the nuclei it emits yellow-green fluorescence. 
Uptake of foreign material by cells leads to activation of di-
gestive vacuoles causing red fluorescence of accumulated 
Acridine orange in the lysosomes (24-26).
An increase in number of the Annexin V-positive melano-
ma cells at their treatment with the Les-3833 is strong ar-
gument in favor of the apoptotic way of death of these 
cells. It was shown that Les-3833 did not affect consider-
ably a number of the Propidium iodide-positive melanoma 
cells that excluded a major role of necrosis during melano-
ma cell killing by this agent. The results of fluorescent mi-
croscopy measuring of the amount of the Annexin V- and 
the PI-positive melanoma cells under the action of the Les-
3833 were comparable to doxorubicin, which indicated 
the anticancer potential of Les-3833.
In order to obtain more direct evidence of apoptosis in-
duced by the Les-3833 in human melanoma WM793 cells, 
the activation of caspase 3 and cleavage of the reparation 
enzyme PARP-1 were monitored by the Western-blot anal-
ysis. We also found that ERK1/2/MAPKs, and EndoG levels 
were increased under the action of the Les-3833. Both cas-
pase 3 and PARP-1 belong to principal biochemical mark-
ers of apoptosis (27), while the protein kinases ERK1/2/
MAPKs were shown to respond the action of various stress-
ing agents, including the anticancer drugs (5,6). PARP-1 
used NAD+ to cause the poly(ADP-ribosyl)ation of proteins 
(27). A design of new anticancer chemotherapeutics is 
intensively developing for creation of novel PARP inhibi-
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tors. Thus, the intactness of PARP-1 and PARP-2 could be 
the prognostic biomarkers at drug development (5,6,27). 
PARP-1 degradation induced by the Les-3833 in human 
melanoma cells demonstrates an additional mechanism in 
the biological action of this potential anticancer drug.
Similar compounds - troglitazones and 3-(2-amino-ethyl)-
5-(4-ethoxybenzylidene)-thiazolidine-2,4-dione - induced 
the inhibition of growth of human pancreatic cancer cells 
and human leukemia cells through the MAPK signaling 
pathway (28-30). It was shown that 5-ene-4-thiazolidino-
nes induced apoptosis in the acute promyelocytic leuke-
mia HL-60 cells via modulating MAPK signaling pathway 
(14). Thus, the activation of MAPK/Erk1/2 pathway in tumor 
cells might be a common mechanism of cytotoxic action 
of 4-thiazolidinones, including the Les-3833, toward hu-
man tumor cells.
It was reported that the mechanisms of anticancer effect 
of 4-thiazolidinones and similar heterocycles could be re-
lated to the activation of caspase cascade, changes in the 
intracellular Ca2+ and mitochondria functioning, a release of 
cytochrome C from mitochondria, and/or the endoplasmic 
reticulum stress (6,28). EndoG (endonuclease G) is a mito-
chondrial protein released at apoptosis, and it is involved 
in caspase-independent DNA degradation (31). EndoG el-
evation induced by the Les-3833 in melanoma cells allow 
one to suggest that these cells undergo apoptosis via the 
mitochondria-mediated pathway. Interestingly, the doxoru-
bicin did not affect the level of the EndoG protein in treated 
melanoma cells that suggested different mechanism of ac-
tion of Les-3833 and doxorubicin in these tumor cells.
STAT3 is a transcription factor involved in regulation of 
expression of different genes under the action of various 
growth factors and cytokines that influence cell growth 
and apoptosis (5,6). STAT3 level was decreased in human 
melanoma WM793 cells treated with the Les-3833 for 72 h, 
while the doxorubicin did not affect the level of this tran-
scription factor. Thus, the action of Les-3833 is mediated 
via various signaling pathways in the cell suggesting a 
uniqueness of this potent anticancer substance. Les-3833 
induced apoptosis in human melanoma cells with an acti-
vation of caspase 3 and influenced the apoptosis-related 
proteins such as PARP, MAPKs, and Endo G. Probably, the 
Les-3833 affected the mitochondria-mediated apoptotic 
pathway (Figure 8).
It was reasonable to compare the action of the Les-3833 
with that of the doxorubicin on cell cycling and the lev-
els of the related regulatory proteins. We have found that 
Les-3833 decreased the level of both Cdk2 and phospho-
rylated form of Rb protein in human melanoma cells of 
WM793 line. The activity of cyclin-dependent kinase 2 is 
important for the G1/S transition, and the retinoblastoma 
protein is a tumor suppressor whose action is impaired in 
many tumors. Inactivation of the Rb protein by phospho-
rylation runs the cell cycle progression (5,32,33). Rb phos-
phorylation in the G1 phase is catalyzed by the CDK2/Cy-
clin E complex, and it is needed for cell transition to the 
S phase (14,33). The Les-3833 and doxorubicin induced 
similar degree in decrease in both the Cdk2 and Rb pro-
teins, however, the distribution of cell cycle phases under 
the action of these drugs differed significantly. While dox-
orubicin, as predicted (14,34), arrested melanoma cells in 
the G2/M phase, the Les-3833 induced the accumulation 
of these cells in the G0/G1 phase. The arrest of tumor cell 
cycling in either G0/G1 or G2/M stages is of great interest, 
and it strongly depends on the expression of cyclin-CDK 
inhibitors - p21 and p27 proteins (32).
ROS are important in the action of several anticancer drugs, 
however, these agents are also damaging cells of normal tis-
sues and organs (negative side effects) (14,17,18,21,35,36). 
The results of our studies suggest that the action of the Les-
3833 in human melanoma WM793 cells is dependent on 
ROS induced by this agent, since NAC and AA blocked the 
cytotoxic effect of the Les-3833. It was reported that dox-
orubicin disturbed a balance of ROS and enzymes of the 
antioxidant defense in blood serum of laboratory rats that 
could be one of the reasons of high general toxicity of this 
anticancer drug. At the same time, 4-thiazolidinones deriva-
tives Les-3288, Les-3833, and Les-3882 were much less ef-
fective there (21). The level of the malonic dialdehyde (in-
dicator of ROS content) was also increased at the Les-3833 
action, although a magnitude of that increase was less than 
at the action of doxorubicin (21). Probably, in the cytotoxic 
action of the Les-3833, ROS play more important role than 
they play it in the action of other 4-thiazolidinones deriva-
tives (Les-3288 and Les-3882). In a recent study, we have 
demonstrated that 5-[5-(2-Hydroxyphenyl)-3-phenyl-4-
,5-dihydropyrazol-1-ylmethylene]-3-(3-acetoxyphenyl)-2-
thioxothiazolidin-4-one that is 5-ene-4-thiazolidinone de-
rivative was highly toxic for human promyelocytic leukemia 
cells of HL-60 line (IC50 = 118 nM) with low toxicity toward 
human embryonic kidney cells of HEK293T line and murine 
mesenchymal preosteoblastic cells of KS 483 line (14). This 
potent drug caused mitochondria-depended apoptosis 
and induced G0/G1 arrest in treated cells. It also acti-
vated ROS production (14).
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Other investigators found that ROS level was increased 
by 5-ene-4-thiazolidinones in human colorectal adeno-
carcinoma HT29 cells and the acute lymphoblastic leuke-
mia CEM cells (18). In addition, the action of many chemo-
therapeutic agents is based on increasing ROS levels, and 
the resulting induction of the irreparable apoptosis-related 
damages in tumor cells (17). ROS-induced apoptosis can 
be linked to the mitochondrial oxidative stress causing cy-
tochrome C release from mitochondria and activation of 
caspases (36).
Conclusion
Toxic action of Les-3833, a novel 4-thiazolidinone derivative, 
toward 7 human tumor cell lines was studied, and human 
melanoma cells of WM793 and SK-Mel-28 lines were found 
to be the most sensitive. Human carcinoma cells of various 
tissue origin, as well as human embryonic kidney cells of 
HEK293 line and human keratinocytes of HaCat line, were 
relatively resistant to such action. Results of Annexin V/PI 
staining of melanoma cells, character of activation of cas-
pase 3, PARP, MAPK, and EndoG protein, and the morpho-
logical changes suggest induction of apoptosis in Les-3833
-treated cells. This agent also induced ROS production in 
melanoma cells and their arrest in G0/G1 phase of cell cycle.
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